pharma · Schizophrenia · Alzheimer's Disease Psychosis · ACAD
Acadia Pharmaceuticals
Acadia Pharmaceuticals B.V.
Acadia Pharmaceuticals is a pharma organization headquartered in Indianapolis, USA. It trades on NYSE under ticker ACAD. Primary therapeutic focus areas include Schizophrenia, Alzheimer's Disease Psychosis, Parkinson Dis
Indianapolis, USA HQ
17 Employees
Public company Type
ACAD · NYSE Ticker
Company details
- Status
- Public
- HQ
- Indianapolis, USA
- Employees
- 17
- Programs
- 32
- Drugs
- 15
- Patents
- 77
L. helveticus R0052 and B. longum R0175
Approved · other · Attention Deficit Hyperactivity Disorder
L. helveticus R0052 and B. longum R0175 for Attention Deficit Hyperactivity Disorder is a Approved program (other) at Acadia Pharmaceuticals B.V. with 1 ClinicalTrials.gov record(s).
Internal code APB-C1
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Acadia Pharmaceuticals B.V.
- Phase
- Approved
- Modality
- other
- Indication
- Attention Deficit Hyperactivity Disorder
- Status
- active
- Trials
- 1